Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Glossary Glossary
The Body Covers: The 6th Conference on Retroviruses and Opportunistic Infections
Abstract No. 402: Phase I/II Dosing Study of Once-Daily Hydroxyurea (HU) Alone vs Didanosine (ddI) Alone vs ddI + HU

February 2, 1999

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

Dr. Frank and colleagues presented 24 week results of a phase I/II, randomized, placebo-controlled five-arm study comparing HU alone at two doses (1000 mg a day and 1500 a day), ddI alone (200 mg twice a day), and ddI/HU in treatment naïve and experienced subjects. The HU groups had ddI added after week 4; the ddI group had HU (1000 mg or 1500 mg) added after week 12. The study enrolled 134 patients, 45% of whom had had no previous antiretroviral experience.

The following table shows the mean changes in viral load (in log copies/ml), followed by the percentage of patients with viral loads below 400 copies/mL on each arm. No statistically significant differences in activity were seen comparing the low and high dose HU + ddI arms (which were therefore combined in the table below) or the treatment-naïve versus treatment-experienced subjects:


  Week 4 Week 8 Week 12 Week 24
Combined HU monotherapy -0.01 n/a n/a -1.05 (23%)
ddI monotherapy -0.84 (22%) -0.83 (19%) -0.85 (30%) -0.79 (30%)
Combined ddI + HU -1.50 (42%) -1.57 (48%) -1.57 (39%) -1.22 (34%)


Neutropenia, or low white blood cell counts, were more likely in the higher dose HU arm.

The study authors concluded that HU alone had no antiretroviral activity, but was synergistic with ddI. However, patients already on ddI had no change in viral load after adding HU at Week 12, so the authors recommend starting both treatments together.

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

Abstract: Phase I/II Dosing Study of Once-Daily Hydroxyurea (HU) Alone vs Didanosine (ddI) Alone vs ddI + HU
Authored by: I. Frank, H. Boucher, S. Fiscus, C. Flexner, F. Valentine, R. Gulick, L. Fox, and J. Eron for the ACTG 307 Team

See Also
More Research on HIV/AIDS Treatment Strategies



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by The Body PRO. Copyright © Body Health Resources Corporation. All rights reserved.


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement